Table 1.
Patient characteristics
| Study | No. of patients | Gender | Diagnosis | Involved sites | Histology at diagnosis | CD20 positivity | EBV reactivation | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | AML | ALL | MDS | AA | CML | CLL | NHL | MM | Extra-nodal sites | CNS | Early-stage disease | Polymorphic | Monomorphic | ( +) | (-) | ( +) | (-) | ||
| Socié et al.2024 | 81 | 49 | 32 | 26 | 13 | 7 | 5 | 4 | 4 | 4 | 0 | 56 | 7 | 2 | 18 | 52 | 52 | 15 | 68 | 3 |
| Lückemeier et al.2023 | 15 | 11 | 4 | 5 | 1 | 1 | 4 | 2 | 0 | 1 | 1 | – | – | 0 | 1 | 8 | 13 | 2 | – | – |
| Rosello et al.2021 | 25 | 13 | 12 | 6 | 3 | 1 | 2 | 7 | – | 0 | 2 | – | 9 | – | 3 | 21 | 19 | 6 | 7 | 2 |
| Salas et al.2020 | 25 | – | – | 16 | 1 | 3 | 0 | 0 | 0 | 5 | 0 | – | – | – | – | – | – | – | – | – |
| Zhu et al.2019 | 27 | 19 | 8 | 11 | 9 | 2 | 4 | 0 | 0 | 1 | 0 | 23 | 1 | – | 2 | – | 8 | – | 27 | 0 |
| Jiang et al.2016 | 84 | 54 | 30 | 39 | 30 | 4 | 9 | 1 | 0 | 1 | 0 | 28 | 10 | 7 | 21 | 0 | – | – | – | – |
| Luo et al.2014 | 5 | 3 | 2 | 0 | 2 | 0 | 1 | 0 | 0 | 2 | – | – | – | 1 | 2 | – | – | – | 4 | – |
| Styczynski et al.2013 | 144 | – | – | – | – | – | – | – | – | – | – | 61 | – | – | 17 | 72 | 77 | 10 | – | – |
| Chen et al.2013 | 17 | 13 | 4 | 9 | 6 | 1 | 1 | 0 | 0 | 0 | 0 | – | – | 5 | 5 | 4 | – | – | 15 | – |
| Czyzewski et al.2013 | 8 | 3 | 5 | 2 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | – | 8 | – | – | – | – | – | 8 | – |
| Total | 431 | 165 | 97 | 114 | 67 | 19 | 28 | 18 | 14 | 3 | 168 | 35 | 15 | 69 | 157 | 169 | 33 | 68 | 5 | |
AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, MDS myelodysplastic syndromes, AA aplastic anemia, CML chronic myeloid leukemia, CLL chronic lymphoblastic leukemia, NHL non-Hodgkin lymphoma, MM multiple myeloma, DLBCL diffuse large B cell lymphoma